Bipolar Disorder, Depressive Disorder, Psychosis, Schizo Affective Disorder, Schizophrenia
Conditions
Keywords
Clinician Training, AI (artificial Intelligence), Machine learning, NLP (natural language processing), Cognitive Behavioral Therapy (CBT)
Brief summary
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp). CBTpro will provide a rapid means of scaling and sustaining high-quality CBTp in routine care settings across the US.
Detailed description
This fast-track Small Business Technology Transfer (STTR) grant is a partnership between the University of Washington and private company LYSSN that includes the development and iterative testing of CBTpro, a Computerized Clinician Support Tool designed to teach behavioral health providers and students Cognitive Behavioral Therapy for psychosis (CBTp). CBTpro uses natural language processing to provide automated speech-to-text and machine learning to score trainee's responses to simulated patients with psychosis. Once technical reliability of the tool is achieved through iterative modifications based on usability and field trials, a randomized control trial will be conducted to assess CBTpro training vs. training as usual with N=100 providers / N=300 clients on clinician skills and client outcomes.
Interventions
BEHAVIORALCBTpro
CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
Sponsors
University of Washington
National Institute of Mental Health (NIMH)
Lyssn.io, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Client Inclusion: Adults who speak English, meet with their provider who is participating in the study at least bi-weekly (2x a month), and do not plan to leave services in the next 6 months. Qualifying diagnoses for clients include: schizophrenia; schizoaffective disorder; schizophreniform disorder; delusional disorder; other specified schizophrenia spectrum and other psychotic disorder; unspecified schizophrenia spectrum or other psychotic disorder; bipolar disorder with psychotic features; major depressive disorder with psychotic features
Exclusion criteria
Dx of psychosis secondary to substance intoxication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Revised Green Paranoid Thoughts Scale (R-GPTS) Mean Score | 0,3,6 months | The Revised Green Paranoid Thoughts Scale (R-GPTS) is a self-report measure of paranoid thinking over the past month, consisting of two validated subscales: Subscale A: Ideas of Reference (0-32) and Subscale B: Ideas of Persecution (0-40). Items are rated from 0 ("Not at all") to 4 ("Totally"), and each subscale is scored independently by summing item responses, with higher scores indicating greater severity. Scores ≥18 on the Persecution scale indicate clinically severe paranoid ideation. This measure was only collected and reported for client participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in CHOICE-SF (Choice of Outcome in CBT for Psychosis- Short Form) | 0,3,6 months | The CHOICE-SF is a 12-item self-report questionnaire designed to assess perceived progress toward recovery among individuals receiving cognitive behavioral therapy for psychosis (CBTp). Each item is rated on a scale from 0 ("Not at all") to 10 ("Extremely") with the exception of the final question which is open-entry. Total scores range from 0 to 110, with higher scores reflecting greater perceived progress in psychological recovery. An increase in the CHOICE-SF score indicates improvement in recovery; a decrease suggests reduced perceived progress.This measure was only collected and reported for client participants. |
| Change in in Sheehan Disability Scale (SDS) Mean Score | 0,3,6 months | The Sheehan Disability Scale (SDS) is a 3-item self-report measure that assesses functional impairment in three domains: work/school, social life, and family life/home responsibilities. Each item is rated on an 11-point scale from 0 ("Not at all impaired") to 10 ("Extremely impaired"). The total score ranges from 0 to 30, with higher scores indicating greater functional impairment. A decrease in the total score reflects improved functioning. This measure was only collected and reported for client participants. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSarah Kopelovich, PhD
University of Washington
Participant flow
Recruitment details
Community mental health clinics were recruited and randomized to one of two training conditions (CBTpro vs. TAU). Eligible providers at each site participated along with three clients during the training period. Client data, including clinical outcomes associated with provider training, are reported on.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 42.83 years STANDARD_DEVIATION 13.97 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 21 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 143 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 8 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 45 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 121 Participants |
| Sex/Gender, Customized Gender Identity Female | 41 Participants |
| Sex/Gender, Customized Gender Identity Male | 16 Participants |
| Sex/Gender, Customized Gender Identity Non-binary or non-gender conforming | 3 Participants |
| Sex/Gender, Customized Gender Identity Other | 1 Participants |
| Sex/Gender, Customized Gender Identity Transgender FTM | 0 Participants |
| Sex/Gender, Customized Gender Identity Transgender MTF | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 173 | 0 / 206 | 0 / 112 | 0 / 110 |
| other Total, other adverse events | 0 / 173 | 0 / 206 | 0 / 112 | 0 / 110 |
| serious Total, serious adverse events | 0 / 173 | 0 / 206 | 0 / 112 | 0 / 110 |
Outcome results
None listed